Global Pericardium Diseases Market Research Report- Forecast till 2023

Global Pericardium Diseases Market Research Report- Forecast till 2023

ID: MRFR/HC/3467-HCRR | | Region: Global | 85 pages | Half-Cooked Research Reports

Global Pericardium Diseases Market Research Report: By Types (Acute Pericarditis, Hemopericardium, Pericarditis, Tuberculosis Pericarditis), Treatment (Diagnostic Test, Disease Treatment), End Users (Hospital & Clinics, Ambulatory Centers) - Forecast till 2023 


Market Scenario:


The pericardium is a double-layered, tough, collagenous membrane, which surrounds the heart. They play an important role in the protection of the health from external shock. Nowadays, a number of companies manufacture artificial tissue membrane, which is widely used in the surgical procedures of pelvic floor reconstruction and bariatric stomach reduction. Many factors are responsible for the diseases, which includes infections, heart surgery, trauma, cancer and many other diseases. Pericarditis is the most common type of the disease. It affects people of all ages, however, men between 20 years-50 years are more likely to develop the disease. In 15%-30% cases, it develops into chronic pericarditis. Increasing prevalence of pericarditis across the globe is a major driver of the market. According to the Health Grades Inc, 1 in every 2,000 individual have pericarditis. Additionally, high healthcare expenditure, increasing demand for the better treatment, and rising number of patients with heart diseases are providing support for the growth of the market. However, available treatments are costly and are not affordable to peoples in developing countries. Thus, the high cost of the treatment may slow the growth of the market.


The global pericardium diseases market is expected to grow at a CAGR of ~8.2 % during the forecast period 2017-2023. 


Intended Audience



  • Pharmaceutical Companies

  • Government and private research companies

  • Research and Development (R&D) Companies

  • Drug Manufacturers and Suppliers

  • Medical Research Laboratories 


Figure 1- Market Synopsis of the Global Pericardium Diseases Market Research, by Region, 2016 (%)

Pericardium Diseases Market


Sources- WHO, cancer research UK, American Cancer Society, press release, annual report


 


Segmentation
The global pericardium diseases market is segmented on the basis of types, treatment, and end users.


On the basis of the types, the market is segmented into acute pericarditis, hemopericardium, pericarditis, tuberculous pericarditis, and others.


On the basis of the treatment, the market is segmented into diagnostic test, and disease treatment. The diagnostic treatment is further segmented into the physical exam, EKG, chest X-ray, echocardiography, cardiac CT, cardiac MRI, and others. The diseases treatment is sub-segmented into anti-inflammatory drugs, pericardium patches, surgery, and others.


On the basis of the end users, the market is segmented into hospital & clinics, ambulatory centers, and others. 


Regional Analysis
The Americas account for the major share of the global pericardium diseases market owing to the increasing number of patients with pericardium diseases, well-developed technology, and increasing government support for research & development. Additionally, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas pericardium diseases market. Presence of major players in this region is likely to support the growth of the market during the forecasted period.
Europe holds the second largest pericardium diseases market, which is followed by Asia Pacific. Strong government support and availability of the funds for research & development have driven the market growth. Germany and the U.K are the major contributors to the market. Asia Pacific is the fastest growing pericardium diseases market owing to the presence rapidly developing the economy, increasing the prevalence of cancer and other heart diseases, and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa, and limited availability of funds and medical facilities. The Middle East dominates the Middle East & Africa pericardium disease market due to the presence of well-developed countries like Kuwait, Qatar, Oman, and South Arabia. However, due to the presence of a huge opportunity for the development of the market, Africa region is expecting a healthy growth.


Market Assessment

Global Pericardium Diseases Market


Sources- WHO, cancer research UK, American Cancer Society, press release, annual report


 


Key Players in Global Pericardium Market


Some of key the players in the market are Smith and Nephew (U.K), Teva Pharmaceutical (Isreal), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Arthrex, Inc.(U.S.), Medtronic (U.K), Edwards Lifesciences (U.S.), Abbott Laboratories (U.S.), Johnson & Johnson Services, Inc. (U.S.), C.R. Bard Inc (U.S.)Allergan (U.S.), Integra Lifesciences (U.S.), Livanova(U.K), and Zimmer Biomet (U.S.)

TABLE OF CONTENT    

Chapter 1.    Report Prologue    

Chapter 2.    Market Introduction    


      2.1    Definition    

      2.2    Scope of the Study    

            2.2.1    Research Objective    

            2.2.2    Assumptions    

            2.2.3    Limitations    

Chapter 3.    Research Methodology

      3.1    Introduction

      3.2    Primary Research    

      3.3    Secondary research    

      3.4    Market Size Estimation

Chapter 4.    Market Dynamics

      4.1    Drivers    

      4.2    Restrains

      4.3    Opportunities    

      4.4    Challenges

      4.5    Macroeconomic Indicators

      4.6    Technology Trends & Assessment            

Chapter 5.    Market Factor Analysis

      5.1    Porters Five Forces Analysis

            5.1.1    Bargaining Power of Suppliers    

            5.1.2    Bargaining Power of Buyers

            5.1.3    Threat of New Entrants    

            5.1.4    Threat of Substitutes    

            5.1.5    Intensity of Rivalry    

      5.2    Value Chain Analysis

      5.3    Investment Feasibility Analysis    

      5.4    Pricing Analysis

Chapter 6.    Global Pericardium Diseases Market, by Types

     6.1    Introduction

      6.2    Acute Pericarditis

Market Estimates & Forecast, 2017 – 2023

      6.3    Hemopericardium

Market Estimates & Forecast, 2017 – 2023

      6.4    Pericarditis

Market Estimates & Forecast, 2017 – 2023

      6.5    Tuberculous Pericarditis

Market Estimates & Forecast, 2017 – 2023

      6.6    Others

Chapter 7.    Global Pericardium Diseases Market, by Treatment

    7.1    Introduction

      7.2    Diagnostic Test

Market Estimates & Forecast, 2017 – 2023

            7.2.1     Physical Exam

                7.2.1.1    EKG

                7.2.1.2    Chest X Ray

                7.2.1.3    Echocardiography

                7.2.1.4    Cardiac CT

                7.2.1.5    Cardiac MRI

                7.2.1.6    Others

      7.3    Disease Treatment

Market Estimates & Forecast, 2017 – 2023

            7.4.1    Anti-Inflammatory Drugs

            7.4.2    Pericardium Patches

            7.4.3    Surgery

            7.4.4    Others

Chapter 8    Global Pericardium Diseases Market, by End User

      8.1    Introduction

      8.2    Hospital & Clinics

Market Estimates & Forecast, 2017 – 2023

      8.3    Ambulatory Centers

Market Estimates & Forecast, 2017 – 2023

      8.4    Others

Chapter 9.    Global Pericardium Diseases Market, by Region

      9.1    Introduction

      9.2    America

            9.2.1    North America

                9.2.1.1    US

                9.2.1.1    Canada

            9.2.2    South America

      9.3    Europe

            9.3.1    Western Europe

                9.3.1.1    Germany

                9.3.1.2    France

                9.3.1.3    Italy

                9.3.1.4    Spain

                9.3.1.5    UK

                9.3.1.6    Rest of Western Europe

            9.3.2    Eastern Europe

      9.4    Asia Pacific

            9.4.1    Japan

            9.4.2    China

            9.4.3    India

            9.4.4    Australia

            9.4.5    Republic of Korea

            9.4.6    Rest of Asia Pacific

      9.5    The Middle East & Africa

            9.5.1    United Arab Emirates

            9.5.2     Saudi Arabia

            9.5.3    Oman

            9.5.4    Kuwait

            9.5.5    Qatar

            9.5.6    Rest of the Middle East & Africa

Chapter 10    Company Landscape    

      10.1    Introduction    

      10.2    Market Share Analysis    

      10.3    Key Development & Strategies    

            10.3.1    Key Developments    

Chapter 11    Company Profiles    

      11.1    Smith and Nephew     

            11.1.1    Company Overview    

            11.1.2    Product Overview    

            11.1.3    Financials    

            11.1.4    SWOT Analysis    

      11.2    GlaxoSmithKline Plc.    

            11.2.1    Company Overview    

            11.2.2    Product Overview    

            11.2.3    Financial Overview    

            11.2.4    Key Developments    

            11.2.5    SWOT Analysis    

      11.3    Bayer AG    

            11.3.1    Company Overview    

            11.3.2    Product Overview    

            11.3.3    Financial Overview

            11.3.4    Key Development    

            11.3.5    SWOT Analysis    

      11.4    Novartis AG

            11.4.1    Company Overview    

            11.4.2    Product/Business Segment Overview    

            11.4.3    Financial Overview    

            11.4.4    Key Development    

            11.4.5    SWOT Analysis    

      11.5    Teva Pharmaceutical 

            11.5.1    Company Overview    

            11.5.2    Product Overview    

            11.5.3    Financial overview    

            11.5.4    Key Developments    

      11.6    Arthrex, Inc.    

            11.6.1    Company Overview    

            11.6.2    Product Overview    

            11.6.3    Financial Overview    

            11.6.4    Key Developments    

      11.7    Eli Lilly and Company

            11.7.1    Overview

            11.7.2    Product Overview

            11.7.3    Financial

            11.7.4    Key Developments    

            11.7.5    SWOT Analysis    

    11.8    Others

Chapter 12    MRFR Conclusion    

      12.1    Key Findings    

            12.1.1    From CEO’s View Point    

            12.1.2    Unmet Needs of the Market    

      12.2    Key Companies to Watch    

      12.3    Prediction of Pharmaceutical industry

Chapter 13    Appendix

LIST OF TABLES

Table 1        Pericardium Diseases Industry Synopsis, 2017 – 2023

Table 2        Global Pericardium Diseases Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3        Global Pericardium Diseases Market by Region, 2017 – 2023, (USD Million)

Table 4        Global Pericardium Diseases Market by Types, 2017 – 2023, (USD Million)

Table 5        Global Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 6        Global Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 7        North America Pericardium Diseases Market by Types, 2017 – 2023, (USD Million)

Table 8        North America Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 9        North America Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 10    US Market by Types, 2017 – 2023, (USD Million)

Table 11    US Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 12    US Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 13    Canada Market by Types, 2017 – 2023, (USD Million)

Table 14    Canada Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 15    Canada Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 16    South America Market by Types, 2017 – 2023, (USD Million)

Table 17    South America Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 18    South America Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 19    Europe Market by Types, 2017 – 2023, (USD Million)

Table 20    Europe Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 21    Europe Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 22    Western Europe Market by Types, 2017 – 2023, (USD Million)

Table 23    Western Europe Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 24    Western Europe Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 25    Eastern Europe Market by Types, 2017 – 2023, (USD Million)

Table 26    Eastern Europe Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 27    Eastern Europe Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 28    Asia Pacific Market by Types, 2017 – 2023, (USD Million)

Table 29    Asia Pacific Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 30    Asia Pacific Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

Table 31    Middle East & Africa Market by Types, 2017 – 2023, (USD Million)

Table 32    Middle East & Africa Pericardium Diseases Market by Treatment, 2017 – 2023, (USD Million)

Table 33    Middle East & Africa Pericardium Diseases Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1    Research Process

Figure 2    Segmentation for Global Pericardium Diseases Market

Figure 3    Segmentation Market Dynamics for Global Pericardium Diseases Market

Figure 4    Global Pericardium Diseases market Share, by Type 2016

Figure 5    Global Pericardium Diseases market Share, by Treatment 2016

Figure 6    Global Pericardium Diseases Market Share, by End Users, 2016

Figure 7    Global Pericardium Diseases Market Share, by Region, 2016

Figure 8    North America Pericardium Diseases Market Share, by Country, 2016

Figure 9    Europe Pericardium Diseases Market Share, by Country, 2016

Figure 10    Asia Pacific Pericardium Diseases Market Share, by Country, 2016

Figure 11    Middle East & Africa Pericardium Diseases Market Share, by Country, 2016

Figure 12    Global Pericardium Diseases Market: Company Share Analysis, 2016 (%)

Figure 13    Smith and Nephew: Key Financials

Figure 14    Smith and Nephew: Segmental Revenue

Figure 15    Smith and Nephew: Geographical Revenue

Figure 16    GlaxoSmithKline Plc..: Key Financials

Figure 17    GlaxoSmithKline Plc..: Segmental Revenue

Figure 18    GlaxoSmithKline Plc..: Geographical Revenue 

Figure 19    Bayer AG: Key Financials

Figure 20    Bayer AG: Segmental Revenue

Figure 21    Bayer AG: Geographical Revenue

Figure 22    Novartis AG: Key Financials

Figure 23    Novartis AG: Segmental Revenue

Figure 24    Novartis AG: Geographical Revenue

Figure 25    Teva Pharmaceutical: Key Financials

Figure 26    Teva Pharmaceutical: Segmental Revenue

Figure 27    Teva Pharmaceutical: Geographical Revenue

Figure 28    Arthrex, Inc.: Key Financials

Figure 29    Arthrex, Inc.: Segmental Revenue

Figure 30    Arthrex, Inc.: Geographical Revenue

Figure 31    Eli Lilly and Company: Key Financials

Figure 32    Eli Lilly and Company: Segmental Revenue

Figure 33    Eli Lilly and Company: Geographical Revenue